← Browse by Condition
Medical Condition
lung diseases
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 3
Pulmonary clinical trials span chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and rare ILDs β€” each with distinct pathophysiology and treatment targets. IPF research is particularly active, building on pirfenidone and nintedanib to identify anti-fibrotic combinations that slow disease more effectively.
Trials include inhaled triple combinations for COPD (LABA/LAMA/ICS), treprostinil subcutaneous for PAH, PDE4B inhibitors, anti-CCL2 antibodies for fibrosis, and aerosol gene therapy for CF (CFTR modulators plus mRNA). FEV1, 6-minute walk distance, and lung function decline remain core endpoints with patient-reported outcomes gaining weight.
Frequently Asked Questions — lung diseases Clinical Trials
How many clinical trials are currently recruiting for lung diseases?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for lung diseases, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lung diseases?
lung diseases research spans Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lung diseases clinical trial?
Eligibility criteria for lung diseases trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2 3
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06758700 Phase 2
Recruiting
Enrollment
15 pts
Location
China
Sponsor
Shanghai Pulmonary Hospital, S...
NCT06431633 Phase 3
Recruiting
Enrollment
129 pts
Location
Spain
Sponsor
Fundación GECP
NCT04307615
Recruiting
Enrollment
90 pts
Location
Sweden
Sponsor
Dalarna County Council, Sweden
NCT05922761 Phase 2
Recruiting
Enrollment
45 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT07356076
Recruiting
Enrollment
400 pts
Location
Czechia
Sponsor
University Hospital Olomouc
NCT05279040
Recruiting
Enrollment
20 pts
Location
Canada
Sponsor
University of British Columbia
NCT06585020 Phase 2
Recruiting
Enrollment
190 pts
Location
France
Sponsor
Centre Hospitalier Universitai...
Related Conditions
extensive stage small cell lung cancer es sclc (1) thoracic neoplasms (1) lung neoplasms (1) carcinoma non small cell lung (1) resectable lung non small cell carcinoma (1) swimming induced pulmonary edema sipe (1) pulmonary edema (1) bronchiolitis obliterans syndrome (1) bronchiolitis obliterans (1) chronic graft versus host disease (1) cystic fibrosis (1) mycobacterium xenopi (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology